1148003-35-3

Basic information

• Product Name: 9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)-
• Synonyms: 9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)-;2-Chloro-9-methyl-6-(4-morpholinyl)-9H-purine;4-(2-Chloro-9-Methyl-9H-purin-6-yl)Morpholine;4-(2-Chloro-9-methyl-purin-6-yl)morpholine;2-Chloro-9-methyl-6-morpholino-9H-purine
• CAS NO: 1148003-35-3
• Molecular Formula: C₁₀H₁₂ClN₅O
• Molecular Weight: 253.68818
• Mol File: 1148003-35-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)-(1148003-35-3)
• EPA Substance Registry System: 9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)-(1148003-35-3)

Safety Data

• Hazardous Substances Data: 1148003-35-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Development:
9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)is utilized as a key intermediate in the synthesis of new drugs and potential therapeutic agents, particularly in the field of medicinal chemistry. Its unique structure, including the chlorine, methyl, and morpholinyl groups, allows for the exploration of novel drug candidates with potential applications in treating various diseases and conditions.
Used in Biochemical Research:
In the realm of biochemical research, 9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)functions as a tool compound for studying a range of biological processes and pathways. Its incorporation into experimental designs facilitates a deeper understanding of molecular mechanisms and interactions, ultimately contributing to the advancement of biological and medical sciences.
Used in Medicinal Chemistry:
9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)is employed as a building block in the design and synthesis of innovative pharmaceutical compounds. Its presence in these molecules can influence their pharmacological properties, such as potency, selectivity, and pharmacokinetics, making it an essential component in the development of more effective and safer medications.
Used in Chemical Synthesis:
As a chemical compound with a distinct structure, 9H-Purine, 2-chloro-9-Methyl-6-(4-Morpholinyl)is also used in various chemical synthesis processes. Its reactivity and functional groups make it a versatile component in the creation of a wide array of chemical products, from pharmaceuticals to specialty chemicals.

Upstream product

• 4010-81-5 4-(2-chloro-9H-purin-6-yl)morpholine 
• 74-88-4 methyl iodide 
• 110-91-8 morpholine 
• 2382-10-7 2,6-dichloro-9-methyl-9H-purine 
• 5451-40-1 2,6 dichloropurine 
• 5451-40-1 2,6-dichloro-7H-purine 

Downstream Products

• 1148003-33-1 2-chloro-9-methyl-6-morpholino-9H-purine-8-carbaldehyde 
• 1198171-79-7 2-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)propan-2-ol 
• 1257378-51-0 C₂₅H₃₆N₈O₂ 
• 1929582-97-7 1-(2-chloro-9-methyl-6-morpholino-9H-purin-8-yl)-N-methylmethanamine 

Relevant articles and documents

Piperazinone substitute or derivative thereof, preparation method and application thereof, and pharmaceutical composition

The invention relates to a piperazinone substitute or a derivative thereof, a preparation method and application thereof, and a pharmaceutical composition, and belongs to the technical field of anti-tumor drugs. The invention designs a piperazinone substituted heterocyclic small molecule compound. The compound shows good affinity to PI3K delta, and the compound can down-regulate the activity of a PI3K pathway in tumor cells, so that the compound shows good inhibitory activity to PI3K delta dependent tumors, and is expected to be used as one of components of a pharmaceutical preparation for treatment of different tumors. The preparation method of the piperazinone substitute is simple and convenient, and the yield is relatively high.

DUAL KINASE-BROMODOMAIN INHIBITORS

Provided herein are compounds of Formula (I) that are dual inhibitors of kinases and bromo-domain proteins. The disclosure also relates to pharmaceutical compositions containing such compounds, methods for using such compounds in the treatment of cancers, particularly, the treatment of multiple myeloma cancers, and to related uses.

PURINES AND METHODS OF THEIR USE

Disclosed are compounds useful in the treatment of neurological disorders. The compounds described herein, alone or in combination with other pharmaceutically active agents, can be used for treating or preventing neurological diseases.

Identification of a potent and selective phosphatidylinositol 3-kinase δ inhibitor for the treatment of non-Hodgkin's lymphoma

PI3Kδ has proved to be an effective target for anti-lymphoma drugs. However, the application of current approved PI3Kδ inhibitors has been greatly limited due to their specific immune-mediated toxicity and increased risk of infection, it is necessary to develop more PI3Kδ inhibitors with new scaffold. In this study, SAR study with respect to piperazinone-containing purine derivatives led to the discovery of a potent and selective PI3Kδ inhibitor, 4-(cyclobutanecarbonyl)-1-((2-(2-ethyl-1H-benzo[d]imidazol-1-yl)-9-methyl-6-morpholino-9H-purin-8-yl)methyl)piperazin-2-one (WNY1613). WNY1613 exhibits good antiproliferative activity against a panel of non-Hodgkin's lymphoma (NHL) cell lines by inducing cancer cell apoptosis and inhibiting the phosphorylation of PI3K and MAPK downstream components. In addition, it can also prevent the tumor growth in both SU-DHL-6 and JEKO-1 xenograft models without observable toxicity. WNY1613 thus could be developed as a promising candidate for the treatment of NHL after subsequent extensive pharmacodynamics and pharmacokinetics investigation.

Development of Purine-Based Hydroxamic Acid Derivatives: Potent Histone Deacetylase Inhibitors with Marked in Vitro and in Vivo Antitumor Activities

In the present study, a series of novel histone deacetylase (HDAC) inhibitors using the morpholinopurine as the capping group were designed and synthesized. Several compounds demonstrated significant HDAC inhibitory activities and antiproliferative effects against diverse human tumor cell lines. Among them, compound 10o was identified as a potent class I and class IIb HDAC inhibitor with good pharmaceutical profile and druglike properties. Western blot analysis further confirmed that 10o more effectively increased acetylated histone H3 than panobinostat (LBH-589) and vorinostat (SAHA) at the same concentration in vitro. In in vivo efficacy evaluations of HCT116, MV4-11, Ramos, and MM1S xenograft models, 10o showed higher efficacy than SAHA or LBH-589 without causing significant loss of body weight and toxicity. All the results indicated that 10o could be a suitable candidate for treatment of both solid and hematological cancer.

Potent and highly selective benzimidazole inhibitors of PI3-kinase delta

Inhibition of PI3Kδ is considered to be an attractive mechanism for the treatment of inflammatory diseases and leukocyte malignancies. Using a structure-based design approach, we have identified a series of potent and selective benzimidazole-based inhibitors of PI3Kδ. These inhibitors do not occupy the selectivity pocket between Trp760 and Met752 that is induced by other families of PI3Kδ inhibitors. Instead, the selectivity of the compounds for inhibition of PI3Kδ relative to other PI3K isoforms appears to be due primarily to the strong interactions these inhibitors are able to make with Trp760 in the PI3Kδ binding pocket. The pharmacokinetic properties and the ability of compound 5 to inhibit the function of B-cells in vivo are described.

BICYCLIC INDOLE-PYRIMIDINE PI3K INHIBITOR COMPOUNDS SELECTIVE FOR P110 DELTA, AND METHODS OF USE

Formula I (Ia and Ib) compounds wherein (i) X1 is N and X2 is S, (ii) X1 is CR7 and X2 is S, (iii) X1 is N and X2 is NR2, (iv) X1 is CR7 and X2 is O, or (v) X1 is CR7 and X2 is NR2, including stereoisomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PBK, and for treating disorders mediated by lipid kinases such as inflammation, immunological, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.

PURINE PI3K INHIBITOR COMPOUNDS AND METHODS OF USE

Purine compounds of Formula I, and including stereoisomers, geometric isomers, tautomers, solvates, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting lipid kinases including p110 alpha and other isoforms of PI3K, and for treating disorders such as cancer mediated by lipid kinases. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.